Discusses the immunologic classification of poliomyelitis virus strains as a step toward effective vaccines.
Supports multivalent polio vaccine strategies; leaves open cross-protection between types in clinical settings.
Within the last three or four years a number of discoveries have raised high hopes for the ultimate solution of one of the major problems in the conquest of poliomyelitis — the prevention of its crippling effects. Some of the major accomplishments that point to ultimate success may be enumerated.Studies of the immunologic classification of strains of poliomyelitis virus from various sources have indicated that, for practical purposes, only three varieties need be considered; they are now referred to as Type 1 for those having the Brunhilde strain as their prototype, Type 2 for those resembling the Lansing strain . . .
No takes yet. Share an insight, caveat, or question.
A 1953 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: